| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | 9.9% | $50,277,776 | 22,647,647 | Point72 Asset Management, L.P. | 17 Oct 2025 | |||
| Soleus Capital Master Fund, L.P. | 10% | $19,791,153 | 10,361,860 | Soleus Capital Master Fund, L.P. | 31 Dec 2025 | |||
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | $20,959,588 | +$20,959,588 | 9,441,256 | RA Capital Management, L.P. | 17 Oct 2025 | ||
| MORGAN STANLEY | 9.3% | +37% | $17,140,705 | +$8,067,473 | 8,974,191 | +89% | Morgan Stanley | 31 Dec 2025 |
| Lynx1 Capital Management LP | 7.3% | $13,557,434 | 7,098,133 | Lynx1 Capital Management LP | 31 Dec 2025 | |||
| Bain Capital Life Sciences Fund II, L.P. | 6.2% | $13,453,200 | 6,060,000 | BCLS II Equity Opportunities, LP | 17 Oct 2025 | |||
| WASATCH ADVISORS LP | 6.8% | -34% | $10,773,085 | -$5,817,712 | 4,852,741 | -35% | Wasatch Advisors LP | 30 Sep 2025 |
| BlackRock, Inc. | 2.5% | $2,513,362 | 1,756,613 | BlackRock, Inc. | 30 Jun 2025 | |||
| ORBIMED ADVISORS LLC | 1% | -80% | $1,687,550 | -$5,127,991 | 883,534 | -75% | OrbiMed Capital LLC | 31 Dec 2025 |
As of 31 Dec 2025, 100 institutional investors reported holding 79,802,971 shares of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC). This represents 90% of the company’s total 88,353,400 outstanding shares.
The largest institutional shareholders of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) together control 84% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | 11% | 9,439,328 | 0.03% | $18,029,116 | |
| MORGAN STANLEY | 10% | 8,981,662 | +81% | 0% | $17,154,974 |
| RA CAPITAL MANAGEMENT, L.P. | 9.1% | 8,000,000 | 0.16% | $15,280,000 | |
| Bain Capital Life Sciences Investors, LLC | 8.1% | 7,171,910 | +545% | 1% | $13,698,348 |
| Lynx1 Capital Management LP | 8% | 7,098,133 | 0% | 2.7% | $13,557,434 |
| VANGUARD GROUP INC | 5% | 4,379,815 | +37% | 0% | $8,365,446 |
| WASATCH ADVISORS LP | 4.9% | 4,344,918 | -10% | 0.05% | $8,298,793 |
| Soleus Capital Management, L.P. | 4.3% | 3,803,942 | -46% | 0.31% | $7,265,529 |
| BANK OF AMERICA CORP /DE/ | 2.7% | 2,387,586 | +16% | 0% | $4,560,290 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 2.3% | 1,994,224 | +5.1% | 0.55% | $3,808,968 |
| BlackRock, Inc. | 2.2% | 1,969,814 | +23% | 0% | $3,762,346 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2% | 1,775,783 | +245% | 0% | $3,391,746 |
| RENAISSANCE TECHNOLOGIES LLC | 1.8% | 1,602,580 | +71% | 0% | $3,060,928 |
| TWO SIGMA INVESTMENTS, LP | 1.7% | 1,509,603 | +81% | 0% | $2,883,342 |
| ORBIMED ADVISORS LLC | 1.6% | 1,404,902 | -73% | 0.06% | $2,683,363 |
| MILLENNIUM MANAGEMENT LLC | 1.3% | 1,188,969 | -39% | 0% | $2,270,931 |
| GOLDMAN SACHS GROUP INC | 1.2% | 1,089,020 | +137% | 0% | $2,080,028 |
| TWO SIGMA ADVISERS, LP | 1.2% | 1,068,200 | +40% | 0% | $2,040,262 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.1% | 988,878 | +36% | 0% | $1,889,264 |
| JANE STREET GROUP, LLC | 0.99% | 874,794 | +330% | 0% | $1,670,856 |
| WELLS FARGO & COMPANY/MN | 0.92% | 809,260 | +4237% | 0% | $1,545,687 |
| ACADIAN ASSET MANAGEMENT LLC | 0.74% | 657,173 | +413% | 0% | $1,251,000 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.51% | 449,432 | +28% | 0% | $858,415 |
| CITADEL ADVISORS LLC | 0.51% | 447,808 | -7% | 0% | $855,313 |
| Walleye Capital LLC | 0.5% | 443,341 | 0% | $846,781 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 79,802,971 | $152,420,218 | +$51,938,383 | $1.91 | 100 |
| 2025 Q3 | 52,538,995 | $116,636,299 | -$3,488,602 | $2.22 | 96 |
| 2025 Q2 | 54,715,914 | $78,242,864 | -$14,672,718 | $1.43 | 102 |
| 2025 Q1 | 64,100,740 | $102,562,013 | -$12,577,745 | $1.60 | 113 |
| 2024 Q4 | 64,400,415 | $231,841,449 | -$9,805,080 | $3.60 | 113 |
| 2024 Q3 | 64,180,724 | $365,858,667 | +$21,073,945 | $5.70 | 118 |
| 2024 Q2 | 60,887,928 | $281,302,982 | +$5,545,189 | $4.62 | 114 |
| 2024 Q1 | 58,201,499 | $475,505,218 | +$93,890,692 | $8.17 | 104 |
| 2023 Q4 | 47,001,017 | $265,585,658 | +$85,422,229 | $5.65 | 91 |
| 2023 Q3 | 34,671,251 | $64,488,483 | -$134,435 | $1.86 | 82 |
| 2023 Q2 | 34,220,399 | $94,120,957 | -$9,383,233 | $2.75 | 96 |
| 2023 Q1 | 37,418,446 | $117,492,869 | -$15,156,032 | $3.14 | 117 |
| 2022 Q4 | 39,224,213 | $231,404,815 | -$9,766,681 | $5.90 | 113 |
| 2022 Q3 | 39,456,577 | $346,000,579 | -$2,524,371 | $8.77 | 115 |
| 2022 Q2 | 39,425,650 | $297,247,580 | -$39,977,861 | $7.54 | 111 |
| 2022 Q1 | 37,306,180 | $904,604,832 | +$6,530,479 | $24.26 | 120 |
| 2021 Q4 | 35,893,940 | $1,154,835,979 | +$16,687,200 | $32.20 | 115 |
| 2021 Q3 | 34,491,766 | $1,542,710,693 | +$110,759,163 | $44.68 | 110 |
| 2021 Q2 | 31,945,852 | $1,209,520,921 | +$259,679,873 | $37.84 | 106 |
| 2021 Q1 | 25,097,387 | $926,788,055 | +$90,401,887 | $36.99 | 83 |
| 2020 Q4 | 22,706,689 | $743,535,975 | +$718,564,975 | $33.13 | 75 |